It's too costly to run - the crowd alone will be worth a small packet. Relevance work has taken a 25% hit over two years.
Revenue is lower pre Figure eight acquisition in 2018 and COGS is $170m p/a higher.
Math doesn't add up. Enterprise is growing that's where the growth is start focussing on offering LLM's to business on use case basis along with Reka and de concentrate. It has no debt but the sale will give it plenty to work with and even acquire Reka.
Thats ok - this is a very young industry thats evolving very fast just need to stay on the curve and make some shrewed moves.
- Forums
- ASX - By Stock
- APX
- What's wrong with Appen's business?
What's wrong with Appen's business?, page-21
-
- There are more pages in this discussion • 83 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add APX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.98 |
Change
-0.075(3.66%) |
Mkt cap ! $491.9M |
Open | High | Low | Value | Volume |
$2.05 | $2.09 | $1.94 | $7.430M | 3.721M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4047 | $1.98 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.98 | 9436 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 12133 | 1.970 |
7 | 26454 | 1.965 |
9 | 23994 | 1.960 |
10 | 47268 | 1.955 |
16 | 101224 | 1.950 |
Price($) | Vol. | No. |
---|---|---|
1.975 | 2647 | 1 |
1.980 | 10657 | 4 |
1.985 | 15745 | 5 |
1.990 | 42728 | 7 |
1.995 | 28910 | 4 |
Last trade - 11.28am 21/10/2024 (20 minute delay) ? |
Featured News
APX (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online